Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-ALPS: TQB2450 +/- Anlotinib in Stage III NSCLC
NCT04325763Phase 3Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- May 2020
- Primary completion
- Dec 2022
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing TQB2450 + Anlotinib, TQB2450 + Placebo and Placebo (3 arms). Primary endpoint: Progression Free Survival at 33 months. Status: unknown.
02
Drugs
benmelstobartanlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04325763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04325763.